Differential Effect of Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Diabetes ManagementSadanori Okada, Takeshi Morimoto, Hisao Ogawa et al.|Diabetes Care|2011Cited by 20
Aspirin Reduces Cerebrovascular Events in Type 2 Diabetic Patients With Poorly Controlled Blood PressureHirofumi Soejima, Yoshihiko Saito, Mio Sakuma et al.|Circulation Journal|2012Cited by 17
Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: Subanalysis from the JPAD TrialHirofumi Soejima, Yoshihiko Saito, Hisao Ogawa et al.|Journal of Cardiology|2013Cited by 16
Abstract 1584: Epidemiology of Hemorrhagic and Gastrointestinal Adverse Effects of Low-dose Aspirin for Primary Prevention of Atherosclerotic Events in Type 2 Diabetic Patients: Insights From JPAD TrialTakeshi Morimoto, Yoshihiko Saito, Hisao Ogawa et al.|Circulation|2009Cited by 1
Abstract 12161: Dipeptidyl Peptidase IV Inhibitor Therapy Modifies Systolic Blood Pressure in High Blood Pressure Diabetic Patients: Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) 2 TrialHirofumi Soejima, Hisao Ogawa, Takeshi Morimoto et al.|Circulation|2014Cited by 0